genetic technologies (asx: gtg, nasdaq global market: gene) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of dna on health. throughout the asia pacific region, we translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.
Company profile
Ticker
GENE
Exchange
Website
CEO
Jerzy Muchnicki
Employees
Location
Industry (SIC)
Former names
GENETIC TECHNOLOGIES LTD /FI
SEC CIK
GENE stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
23 Apr 24
6-K
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
23 Apr 24
6-K
Company Announcements Office
23 Apr 24
6-K
Current report (foreign)
23 Apr 24
6-K
Genetic Technologies Announces $2 Million Registered Direct Offering
22 Apr 24
424B5
Prospectus supplement for primary offering
22 Apr 24
6-K
Genetic Technologies Announces US$2 Million Registered Direct Offering
19 Apr 24
6-K
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
17 Apr 24
6-K
Current report (foreign)
11 Apr 24
6-K
Current report (foreign)
8 Apr 24
Transcripts
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G
CVI Investments, Inc.
13 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
4 Jun 20
SC 13G
INTRACOASTAL CAPITAL, LLC
28 Apr 20
SC 13G/A
Genetic Technologies LTD
13 Feb 19
SC 13G
Genetic Technologies LTD
14 Feb 18
SC 13G/A
Genetic Technologies LTD
9 Feb 18
SC 13G/A
Genetic Technologies LTD
8 Jan 18
SC 13G/A
Genetic Technologies LTD
14 Feb 17
SC 13G/A
Genetic Technologies LTD
10 Feb 17
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 6 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 268.32 mm |
Total shares | 706.24 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 623.08 mm | $0.00 |
Intracoastal Capital | 83.03 mm | $166.90 mm |
MS Morgan Stanley | 87.66 k | $66.85 mm |
Rhumbline Advisers | 18.70 k | $14.38 mm |
Two Sigma Securities | 15.84 k | $12.08 mm |
Scarborough Advisors | 10.64 k | $8.11 mm |
Proequities | 0.00 | $0.00 |
News
Marijuana Stock Movers For April 25, 2024
25 Apr 24
Cannabis Stock Movers For April 19, 2024
19 Apr 24
Bearish Sentiment Across The Cannabis Space - Check Full Movers For April 18, 2024
18 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Apr 24
Genetic Technologies Announces $2M Registered Direct Offering Of 1M ADS At A Price Of $2/ADS
18 Apr 24
Press releases
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
22 Apr 24
Genetic Technologies Announces $2 Million Registered Direct Offering
18 Apr 24
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
12 Apr 24
GTG to pilot GeneType in Breast Screen centers across the U.S.
11 Apr 24
Genetic Technologies' Digital Strategy Ignites Significant Traction in US Market
2 Apr 24